RxDoctor Payments Data

Dency Rivas, MD

General Practice · Tampa, FLNPI 1861493900

Payments from drug & device makers

$393in general payments, 2019–2025

Across 25 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$189
  • GSK$50
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • Novo Nordisk$33
  • Boehringer Ingelheim$31
  • Lilly USA, LLC$15
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$38798%
  • Education$62%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$393 in reported general payments places this provider in the 55th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$23,533
Medicare patients
45
Services billed
1,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab14$101,176
TrulicityDulaglutide34$45,799
JanuviaSitagliptin Phosphate26$36,916
EliquisApixaban34$26,687
FarxigaDapagliflozin Propanediol26$26,590
OzempicSemaglutide20$24,019
JardianceEmpagliflozin20$20,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,568
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$9,935
TradjentaLinagliptin11$9,414
Tresiba Flextouch U-200Insulin Degludec13$7,546
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,983
Atorvastatin Calcium304$2,650
Albuterol Sulfate HfaAlbuterol Sulfate61$2,583
Aripiprazole63$2,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$15$45,79934 claims
Boehringer IngelheimJardiance, Tradjenta$31$29,73531 claims
PfizerEliquis$14$26,68734 claims
AstraZenecaFarxiga$189$26,59026 claims
Novo NordiskOzempic$33$24,01920 claims
GSKTrelegy Ellipta$50$15,56818 claims
Sanofi-aventis U.S. LLCLantus$13$1,66317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,901 general practice providers in Florida.

Other general practice in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →